Mr. Keith Dewedoff is the Interim Chief Financial Officer of Ceptur Therapeutics. Previously, he served as a CFO Advisor for Danforth Advisors, guiding both public and private biotech companies on financial growth strategies & operational restructurings, as well as the CFO of Kaizen Bioscience, where he is currently on the Board of Directors. Earlier in his career, Mr. Dewedoff was the Head of Corporate FP&A & Strategic Planning for Radius Pharmaceuticals, where he led Finance and Business Planning activities. He has also previously served in multiple global and domestic management consulting roles for various companies, including Johnson & Johnson and Pfizer, as well as in various corporate roles for The Children’s Hospital of Philadelphia, Penn Medicine, and The Philadelphia Stock Exchange (acquired by NASDAQ). Mr. Dewedoff earned his BS in Management & Economics from Northeastern University.
Current role